Addressing vaccine supply challenges in Europe: Expert industry perspective and recommendations.

Autor: Pasté M; Development of this publication; GlaxoSmithKline Biologicals, Avenue Fleming, 20, 1300 Wavre, Belgium. Electronic address: muriel.m.paste@gsk.com., Stoffel M; Development of this publication; GlaxoSmithKline Biologicals, Avenue Fleming, 20, 1300 Wavre, Belgium. Electronic address: michel.stoffel@gsk.com., Bardone C; Sanofi Pasteur, Campus Sanofi Lyon Carteret, 14 espace Henry Vallée 69007 Lyon, France. Electronic address: Corinne.Bardone@sanofi.com., Baron-Papillon F; Sanofi Pasteur, Campus Sanofi Lyon Carteret, 14 espace Henry Vallée 69007 Lyon, France. Electronic address: Florence.BaronPapillon@sanofi.com., Czwarno A; Vaccine Europe, Leopold Plaza Building, Rue du Trône 108, 1050 Brussels, Belgium. Electronic address: anna.czwarno@vaccineseurope.eu., Galbraith H; Pfizer, Belgium, Boulevard de la Plaine 17, 1050 Ixelles, Belgium. Electronic address: Heike.Galbraith@pfizer.com., Gastineau T; Sanofi Pasteur, Campus Sanofi Lyon Carteret, 14 espace Henry Vallée 69007 Lyon, France. Electronic address: Thierry.Gastineau@sanofi.com., Germay O; GlaxoSmithKline Biologicals, Avenue Fleming, 20, 1300 Wavre, Belgium. Electronic address: olivier.c.germay@gsk.com., Gonzo D; MSD, Weystrasse 20, 8006 Lucerne, Switzerland. Electronic address: davide.gonzo@merck.com., Juvin P; Sanofi Pasteur, Campus Sanofi Lyon Carteret, 14 espace Henry Vallée 69007 Lyon, France. Electronic address: paul.l.van-hoof@gsk.com., Kissane J; Pfizer, 32 New Lane, Havant, PO9 2NG, UK. Electronic address: Julia.Kissane@pfizer.com., Laigle V; MSD Vaccins, 162 Avenue Jean Jaures, 69007 Lyon, France. Electronic address: Valerie.laigle@msd.com., Mlynarczyk P; MSD, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, USA. Electronic address: peter_mlynarczyk@merck.com., van Hoof P; GlaxoSmithKline Biologicals, Avenue Fleming, 20, 1300 Wavre, Belgium., Wettendorff M; GlaxoSmithKline Biologicals, Avenue Fleming, 20, 1300 Wavre, Belgium. Electronic address: martine.wettendorff@gsk.com., Quilici S; Vaccine Europe, Leopold Plaza Building, Rue du Trône 108, 1050 Brussels, Belgium. Electronic address: sibilia.quilici@vaccineseurope.eu.

Publikováno v: Health policy (Amsterdam, Netherlands) [Health Policy] 2022 Jan; Vol. 126 (1), pp. 35-42. Date of Electronic Publication: 2021 Nov 28.

The Autonomous Fusion Activity of Human Cytomegalovirus Glycoprotein B Is Regulated by Its Carboxy-Terminal Domain.

Autor: Reuter, Nina¹ (AUTHOR) nina.reuter@uk-erlangen.de, Kropff, Barbara¹ (AUTHOR) barbara.kropff@uk-erlangen.de, Chen, Xiaohan¹ (AUTHOR) xiaohan.chen@uk-erlangen.de, Britt, William J.² (AUTHOR) wbritt@uabmc.edu, Sticht, Heinrich³ (AUTHOR) heinrich.sticht@fau.de, Mach, Michael¹ (AUTHOR) michael.mach@fau.de, Thomas, Marco¹ (AUTHOR) marco.thomas@uk-erlangen.de

Publikováno v: Viruses (1999-4915). Sep2024, Vol. 16 Issue 9, p1482. 20p.

Activation of primary allogeneic CD8+ T cells by dendritic cells generated in vitro from CD34+ cord blood progenitor cells

Autor: Wettendorff M, Massacrier C, Vanbervliet B, Urbain J, Banchereau J, Christophe Caux

Publikováno v: Europe PubMed Central

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::fe7039094d9833e423e1f4c0df5eddfd
https://pubmed.ncbi.nlm.nih.gov/8526096

Comment on "CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy".

Autor: van der Most R; GlaxoSmithKline Vaccines, Rixensart, Rixensart 3090, Belgium. robbert.x.van-der-most@gsk.com., Wettendorff M; GlaxoSmithKline Vaccines, Rixensart, Rixensart 3090, Belgium., Innis B; GlaxoSmithKline Vaccines, King of Prussia, PA 19406, USA., Hanon E; GlaxoSmithKline Vaccines, Rixensart, Rixensart 3090, Belgium.

Publikováno v: Science translational medicine [Sci Transl Med] 2014 Jun 25; Vol. 6 (242), pp. 242le3.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.